Circulating Tumor Cells as Biomarkers in Clinical Development (CTC01)
||Duration: 1 hours (the average time to complete the training program, including final assessments).
Credits Hours: 1
Self-paced Training: 24/7 access to course.
Enrollment Period: 3 months.
Demonstration: Try one of our FREE courses.
Certificate: View sample certificate.
PRICE: USD $95.00
Training Program: Circulating Tumor Cells as Biomarkers in Clinical Development
Training Provided By: BioPharma Institute
Availability: Immediately available upon ordering.
Description: Online training with immediate access upon enrollment. This course discusses how to use Circulating Tumor Cells as Biomarkers during Clinical Development. The topics include: Metastasis and Circulating Tumor Cells (CTCs): Discussion of metastasis and how CTCs disseminate. Analysis of CTCs: How CTCs are captured and analyzed. CTCs as biomarkers: Predictive and prognostic characteristics. CTCs in oncology clinical studies: Discussion of several seminal scientific reports and implementation of CTCs in biomarker studies related to oncology drug development. And much more. Instructor: Dr. Alexander Kuklin. (October, 2010)
Certification Requirements: Students must view the entire program and successfully pass an online, multiple-choice final assessment with >80% passing grade within a 90 day period of time (180 days for Professional Certification Programs). Certificate is accessible in PDF format immediately after satisfying requirements.
Online Training Programs Include:
- Immediate access to training: Instructions, user name, password and receipt of payment emailed instantly upon online enrollment
- Optimized for learning: Courses include voice-overs, easy navigation, progress checks, and high-quality animations to increase retention of subject matter
- Self-paced training: 24/7 access to individual courses for 90 days; and 180 days for professional certification programs
- Flexible final assessments: Tests include multiple-choice questions and can be taken repeatedly until a passing score is achieved
- Direct access to certificates: Documentation instantly available once course requirements have been fulfilled
- Corporate reimbursements: Employers may pay for or reimburse employees for training. Purchase orders (POs) for both individual and group training are accepted
- Corporate LMS solutions: All courses are SCORM compliant and can be delivered from most corporate Learning Management Systems
- Career advancement: Professional certifications may be helpful for those seeking new careers or transitioning to different positions within their organization
The Circulating Tumor Cells as Biomarkers in Clinical Development course is found in the following professional certification program(s):
Circulating Tumor Cells (CTCs) as biomarkers in clinical development.
Non-hematopoietic malignancies are mostly characterized by invasion into other organs.
Dissemination of cancer to other organs causing their destruction.
Incidence of Bone Metastases in Cancers.
Tumor Biology – CTCs and Metastasis.
CTCs penetrate into the blood system.
Metastasis Formation is Highly Inefficient.
Blood collection and centrifugation.
Germ layers and their relevance to detection of CTCs.
Capture of CTCs.
Magnetic capture of CTCs.
Analysis of Tumor Cells.
CTC Expression by Cancer Type: Survey Study.
Key Properties of Cancer Biomarkers.
Specific to cancer.
Assay is standardized, quantitative, and validated.
Measurement can be obtained by non-invasive techniques.
Biomarker stability can be maintained during shipping/storage/assay.
Intra- and inter-observer variability should be minimal.
Modulation of the biomarker correlates with clinical benefit.
Serial monitoring is possible.
Landmark Article, ‘Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer’ Cristofanilli, et al.
A prospective, multicenter study.
WHO Bidimensional CT Imaging.
Partial Response (PR).
Progressive Disease (PD).
Stable Disease (S).
Introduction to Kaplan-Meier.
Non-parametric estimate of the survival function.
Commonly used to describe survivorship of study populations.
Commonly used to compare two study populations.
Intuitive graphical presentation.
CTCs as Prognostic Biomarkers.
Prognostic biomarkers – definition.
Prognostic biomarkers forecast the likely course of disease irrespective of treatment.
CTCs as Predictive Biomarkers.
Predictive biomarkers – definition.
Predictive biomarkers forecast the likely response to treatment.
Clinical Utility of CTCs in monitoring metastatic colorectal cancer (mCRC).
Progression-free survival (PFS).
Overall survival (OS).
Current multicenter studies.
CellTracks? Biomarker Reagents for CTC Characterization.
Temporal profiles: patients with largest number of detectable CTCs at baseline.
Circulating Tumor Cells – FISH Analysis.
Learn about metastasis and how CTCs disseminate.
Learn how CTCs are captured and analyzed and used for their predictive and prognostic characteristics.
Discuss several seminal scientific reports and implementation of CTCs in biomarker studies related to oncology drug development.
For more information on the BioPharma Institute’s training programs, or to suggest a course, please complete the form located below. Alternatively, you may call toll free in the US: (888) 4-BIO-LRN
, international callers can dial (201) 301-8370, or email Support@BioPharmaInstitute.com